- Home
- PETZ vs SNOA Comparison
PETZ vs SNOA Comparison
Compare PETZ & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- SNOA
- Stock Information
- Founded
- PETZ 2002
- SNOA 1999
- Country
- PETZ China
- SNOA United States
- Employees
- PETZ N/A
- SNOA N/A
- Industry
- PETZ Steel/Iron Ore
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- SNOA Health Care
- Exchange
- PETZ Nasdaq
- SNOA Nasdaq
- Market Cap
- PETZ 9.3M
- SNOA 7.5M
- IPO Year
- PETZ 2017
- SNOA 2007
- Fundamental
- Price
- PETZ $1.12
- SNOA $4.43
- Analyst Decision
- PETZ
- SNOA
- Analyst Count
- PETZ 0
- SNOA 0
- Target Price
- PETZ N/A
- SNOA N/A
- AVG Volume (30 Days)
- PETZ 101.4K
- SNOA 109.7K
- Earning Date
- PETZ 04-28-2025
- SNOA 11-06-2025
- Dividend Yield
- PETZ N/A
- SNOA N/A
- EPS Growth
- PETZ N/A
- SNOA N/A
- EPS
- PETZ 0.26
- SNOA N/A
- Revenue
- PETZ $563,726.00
- SNOA $14,912,000.00
- Revenue This Year
- PETZ N/A
- SNOA $23.00
- Revenue Next Year
- PETZ N/A
- SNOA $24.59
- P/E Ratio
- PETZ $5.63
- SNOA N/A
- Revenue Growth
- PETZ 74664.72
- SNOA 17.43
- 52 Week Low
- PETZ $0.65
- SNOA $1.75
- 52 Week High
- PETZ $1.74
- SNOA $6.92
- Technical
- Relative Strength Index (RSI)
- PETZ 58.29
- SNOA 51.27
- Support Level
- PETZ $1.02
- SNOA $4.31
- Resistance Level
- PETZ $1.20
- SNOA $4.68
- Average True Range (ATR)
- PETZ 0.07
- SNOA 0.19
- MACD
- PETZ 0.01
- SNOA -0.08
- Stochastic Oscillator
- PETZ 53.71
- SNOA 21.43
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.